KR20190065296A - 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 - Google Patents

아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 Download PDF

Info

Publication number
KR20190065296A
KR20190065296A KR1020197010786A KR20197010786A KR20190065296A KR 20190065296 A KR20190065296 A KR 20190065296A KR 1020197010786 A KR1020197010786 A KR 1020197010786A KR 20197010786 A KR20197010786 A KR 20197010786A KR 20190065296 A KR20190065296 A KR 20190065296A
Authority
KR
South Korea
Prior art keywords
formulation
acetaminophen
sulfoalkyl ether
ether cyclodextrin
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197010786A
Other languages
English (en)
Korean (ko)
Inventor
제임스 디 피프킨
제럴드 엘 모셔
로저 라쥬스키
Original Assignee
사이덱스 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이덱스 파마슈티칼스, 인크. filed Critical 사이덱스 파마슈티칼스, 인크.
Priority to KR1020237043884A priority Critical patent/KR20240005122A/ko
Publication of KR20190065296A publication Critical patent/KR20190065296A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
KR1020197010786A 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 Ceased KR20190065296A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237043884A KR20240005122A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395794P 2016-09-16 2016-09-16
US62/395,794 2016-09-16
PCT/US2017/051919 WO2018053358A1 (en) 2016-09-16 2017-09-15 Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043884A Division KR20240005122A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형

Publications (1)

Publication Number Publication Date
KR20190065296A true KR20190065296A (ko) 2019-06-11

Family

ID=61619250

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197010786A Ceased KR20190065296A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형
KR1020237043884A Pending KR20240005122A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237043884A Pending KR20240005122A (ko) 2016-09-16 2017-09-15 아세트아미노펜 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형

Country Status (9)

Country Link
US (1) US20190255000A1 (cg-RX-API-DMAC7.html)
EP (1) EP3512511A4 (cg-RX-API-DMAC7.html)
JP (3) JP7181185B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190065296A (cg-RX-API-DMAC7.html)
CN (2) CN116869983A (cg-RX-API-DMAC7.html)
AU (3) AU2017326519B2 (cg-RX-API-DMAC7.html)
CA (1) CA3036989A1 (cg-RX-API-DMAC7.html)
MX (2) MX2019002976A (cg-RX-API-DMAC7.html)
WO (1) WO2018053358A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023224112A1 (cg-RX-API-DMAC7.html) * 2022-05-20 2023-11-23

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
WO2009098716A2 (en) * 2008-01-17 2009-08-13 Aptuit Laurus Private Limited Stable pharmaceutical aqueous compositions
ES2545484T3 (es) * 2009-07-23 2015-09-11 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Formulación de paracetamol inyectable, estable, lista para usar
PH12013500477A1 (en) * 2010-09-13 2018-01-17 Bev Rx Inc Aqueous drug delivery system comprising off-flavor masking agent
CN110066351B (zh) * 2012-02-28 2022-06-14 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法
CN102871994B (zh) * 2012-09-29 2015-07-29 中国科学院大连化学物理研究所 氟比洛芬对乙酰氨基酚酯环糊精包合物及其制备方法
BR102014005885B1 (pt) * 2014-03-13 2021-04-13 Biotec Biológica Indústria Farmacêutica Ltda E.P.P Formulação farmacêutica líquida injetável estável de paracetamol em bolsa plástica pronta para uso
SI3411047T1 (sl) * 2016-02-04 2021-09-30 Czap Research And Development, Llc Sredstva za nadzorovano sproščeni in stratificirani kompleks vključitve ciklodekstrina

Also Published As

Publication number Publication date
JP2019532927A (ja) 2019-11-14
RU2019107764A3 (cg-RX-API-DMAC7.html) 2021-01-15
JP2022140780A (ja) 2022-09-27
EP3512511A1 (en) 2019-07-24
EP3512511A4 (en) 2020-05-20
MX2023003761A (es) 2023-04-26
KR20240005122A (ko) 2024-01-11
AU2023203660A1 (en) 2023-07-06
JP2024051102A (ja) 2024-04-10
JP7181185B2 (ja) 2022-11-30
AU2017326519B2 (en) 2023-03-16
AU2025204233A1 (en) 2025-06-26
CA3036989A1 (en) 2018-03-22
US20190255000A1 (en) 2019-08-22
WO2018053358A1 (en) 2018-03-22
AU2017326519A1 (en) 2019-04-11
RU2019107764A (ru) 2020-10-16
CN116869983A (zh) 2023-10-13
CN110167543A (zh) 2019-08-23
MX2019002976A (es) 2019-07-10

Similar Documents

Publication Publication Date Title
BRPI0921705B1 (pt) composição farmacêutica antimicrobiana e seu uso
US20040209843A1 (en) Aqueous cilostazol preparation for injection
JP2023551145A (ja) 医薬化合物の錯化剤塩製剤
AU2025204233A1 (en) Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin
US20230255919A1 (en) Composition containing cyclodextrin and busulfan
PT1224188E (pt) Composição de administração nasal que compreende o sal metanossulfonato de morfina e quitosano
WO2011111070A2 (en) Novel injectable combination
RU2772384C9 (ru) Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина
RU2772384C2 (ru) Составы, содержащие ацетаминофен и сульфоалкиловый эфир циклодекстрина
JP6073202B2 (ja) 静脈におけるウイルスの治療
KR20140053952A (ko) 피라지노-트리아진 유도체를 포함하는 조성물
EP0348150A2 (en) Use of thromboxane receptor antagonist in renal diseases and dysfunction
US20070129328A1 (en) Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
RU2787621C2 (ru) Композиция, содержащая циклодекстрин и бусульфан
JP2009538822A5 (cg-RX-API-DMAC7.html)
EP3215125B1 (en) Compositions comprising finafloxacin and tris
ES2318551T3 (es) Administracion pulmonar de un compuesto anti-trombotico.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000